Becton, Dickinson and Company (BDXA) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $55.91B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | — | CEO | Thomas E. Polen Jr. |
| IPO Date | 2017-05-11 | CAGR | 7.65% |
| Employees | 72,000 | Website | — |
| Div. Yield | 2.06% | Payout Ratio | 187% |
| Buy Back Yield | 4.47% | Total Yield | 6.53% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $57.68B | P/E | 45.7 | Forward P/E | — | PEG | — |
| P/S | 2.4 | P/B | 2.04 | P/CF | 10.42 | P/FCF | 13.07 |
| Sales | $20.84B | Sales 1Y | -2.56% | Sales 3Y | 9.41% | Sales 5Y | 6.25% |
| EPS | $1.3 | EPS 1Y | -40.29% | EPS 3Y | -39.75% | EPS 5Y | -47.88% |
| Sales QoQ | 5.71% | EPS QoQ | -223.42% | Sales QoQ Avg | -2.11% | EPS QoQ Avg | -110.59% |
| Gross Margin | 46.12% | Operating Margin | 9.83% | Profit Margin | 4.52% | ROCE | 4.96% |
| ROA | 2% | ROE | 4% | Altman Z Score | 2.12 | Piotroski Score | 7 |
| Current Ratio | 0.87 | Quick Ratio | 0.51 | Cash Ratio | 0.08 | Op. CF Ratio | 0.07 |
| Debt/Equity | 0.69 | Debt/Assets | 0.33 | Lt Debt/Equity | 0.55 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | 3.77 | Inventory Turnover | 3.39 | Asset Turnover | 0.41 | Receivables Turnover | 8.82 |
| Enterprise Value | $57.68B | P/E Ratio | 45.7 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 2.4 | P/B Ratio | 2.04 |
| P/CF Ratio | 10.42 | P/FCF Ratio | 13.07 |
| EPS | $1.3 | EPS Growth 1Y | -40.29% |
| EPS Growth 3Y | -39.75% | EPS Growth 5Y | -47.88% |
| Revenue Growth 1Y | -2.56% | Gross Margin | 0.46% |
| Operating Margin | 0.1% | Profit Margin | 0.05% |
| ROE | 0.04% | ROA | 0.02% |
| ROCE | 0.05% | Current Ratio | 0.87 |
| Quick Ratio | 0.51 | Cash Ratio | 0.08 |
| Debt/Equity | 0.69 | Interest Coverage | 3.77 |
| Altman Z Score | 2.12 | Piotroski Score | 7 |
Becton, Dickinson and Company (BDXA) valuation & financials
Becton, Dickinson and Company (BDXA) has a market capitalization of $55.91B and trades at a price-to-earnings ratio of 45.7. It operates in the Healthcare sector (Medical - Instruments & Supplies).
Becton, Dickinson and Company's revenue grew -2.6% over the last year.
Becton, Dickinson and Company (BDXA) — frequently asked questions
What is Becton, Dickinson and Company's market cap?
Becton, Dickinson and Company (BDXA) has a market capitalization of $55.91B.
What is BDXA's P/E ratio?
Becton, Dickinson and Company trades at a price-to-earnings ratio of 45.7, with trailing twelve-month EPS of $1.30.
How fast is Becton, Dickinson and Company growing?
Becton, Dickinson and Company's revenue grew -2.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)